For reprint rights or to purchase a copy of your Daily Journal photo, email jeremy@reprintpros.com for prices or call 949-702-5390.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Health Care & Hospital Law,
Civil Litigation

Apr. 24, 2025

Eli Lilly sues telehealth companies over compounded weight loss drugs

The pharmaceutical company claims the compounded medications lack FDA approval and put patients at risk, while defendants argue Lilly is trying to stifle competition and protect its market dominance.

Eli Lilly sues telehealth companies over compounded weight loss drugs
Photo: KK Stock/Shutterstock

Eli Lilly and Company launched a legal offensive Wednesday against three telehealth startups, accusing them in federal court in San Francisco of conspiring to market and sell unregulated versions of its popular weight loss drug tirzepatide.

In separate complaints filed in San Francisco, the pharmaceutical giant claims the companies--Mochi Health, Fella Health and Delilah, and Henry Meds--misled patients by promoting compounded medications as safe alternatives, despite lacking FDA...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.